Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks! Everything looking promising here. Hope some big Investors will soon come in...
BIOTECHTV video : TCR discussion starts around 15:30 mark of this video - Cantor Fitzgerald
https://www.biotechtv.com/post/eric-schmidt-cantor-fitzgerald-january-22-2024
IMTX: New Presentation - January 22, 2024 ( filed as an exhibit)
https://www.sec.gov/Archives/edgar/data/1809196/000095010324000955/dp205494_ex9903.htm
IMTX: Sec filing regarding recent offering / capital raise - interesting exhibits
https://www.sec.gov/Archives/edgar/data/1809196/000095010324000955/dp205494_6k.htm
This puts the O/S (Outstanding Shares) in and around 100 million.
Theory = Internal squabbling and IMTX is buying out dissenting shareholders.
IMTX: Immatics Announces Pricing of $175 Million Public Offering
https://www.globenewswire.com/news-release/2024/01/18/2811206/0/en/Immatics-Announces-Pricing-of-175-Million-Public-Offering.html
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $175 million. The offering is expected to close on January 22, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,388,750 additional shares at the public offering price, less the underwriting discount.
Jefferies, BofA Securities and Leerink Partners are acting as joint book-running managers for the offering.
A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on August 9, 2021. The offering is being made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained free of charge from
Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 821-7388, email: Prospectus_Department@Jefferies.com;
BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, telephone: (800) 294-1322, email: dg.prospectus_requests@bofa.com;
Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: (800) 808-7525, ext. 6105, email: syndicate@leerink.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
IMTX: recent short report:
https://www.marketbeat.com/stocks/NASDAQ/IMTX/short-interest/
2 million plus increase in short position December 15/23 - December 31/23
"Thanks".... IMTX management
IMTX: https://www.sec.gov/Archives/edgar/data/1809196/000119312524009253/d127760d424b5.htm#supptoc127760_6
Not sure what to think of this. Biggest question, at the moment imo, is why the capital raise when they have enough cash on hand and just received 120 million from Moderna?
Probably tanking tomorrow.
Interesting find! It seem's to me something will happen here in the near future...
Nice volume again!
January 9/25 3:07 ET Level II Ask looking thin, at the moment, especially above $12.25
Volume/Price - on FIRE!!
Sumthing go'ing on at JP Morgan conference??
IMTX: Clinical Trial Review:
1. NCT05958121 IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/?or Refractory Solid Tumors
https://clinicaltrials.gov/study/NCT05958121?spons=immatics&rank=3&tab=table
2. NCT05359445 IMA401 TCER® in Recurrent and/?or Refractory Solid Tumors
https://clinicaltrials.gov/study/NCT05359445?spons=immatics&rank=4&tab=table
3. NCT03686124 ACTengine® IMA203/?IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/?or Refractory Solid Tumors (ACTengine)
https://clinicaltrials.gov/study/NCT03686124?spons=immatics&rank=6&tab=table
Of interest is that all 3 have Data Monitoring Committees
https://www.ppd.com/wp-content/uploads/2020/07/decision-tree-graphic.pdf
IMTX: Immatics to attend meetings at the 42nd Annual J.P. Morgan Healthcare Conference January 8-11/24
https://investors.immatics.com/events-presentations
Immatics Announces Third Quarter 2023 Financial Results and Business Update...
8.30 am conference call....
IMTX: Form 6-k
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/92498872/form-6-k-report-of-foreign-issuer-rules-13a-16
EXCERPT 1:
Development path for IMA203 GEN1 and IMA203CD8 GEN2 monotherapies
The goal of Immatics’ development strategy is to make its cell therapies targeting PRAME available to the broadest possible solid cancer patient population with an initial focus on the US market. To achieve this, Immatics has announced a three-step development strategy for leveraging the full breadth of PRAME, a target that is highly expressed in various solid cancers.
1. Focus on IMA203 GEN1 in cutaneous melanoma (potentially bundled with uveal melanoma), targeted to enter a registration-enabling Phase 2 clinical trial in 2024. Discussions with FDA to align on patient population, clinical trial design and CMC aspects are ongoing under the RMAT designation achieved for IMA203 GEN1 in multiple cancer types including cutaneous and uveal melanoma. There are up to 3,300 HLA-A*02 and PRAME-positive cutaneous and
Immatics Press Release November 8, 2023 5 | 8
uveal melanoma last-line patients per year in the US. A next update on the clinical development plan is expected in the first quarter of 2024.
2. In parallel, commence dedicated dose expansion cohorts for signal finding in ovarian and uterine cancer, preferentially with IMA203CD8 GEN2. Enrollment of patients with these cancer types is already ongoing. There are up to 9,000 HLA-A*02 and PRAME-positive ovarian and uterine last-line cancer patients per year in the US.
3. The development of a broader tumor-agnostic label in PRAME+ solid cancers, including in NSCLC, triple-negative breast cancer, and others. This could leverage the full potential of PRAME across multiple solid cancer types.
IMTX: Press Release Nov.8/23
https://finance.yahoo.com/news/immatics-reports-interim-clinical-data-120000187.html
Interim clinical data out...
Thank u! Seems to have the knowledge in the sector...
Hope to see another nice day with buying pressure...
IMTX: New analyst coverage from Cantor Fitzgerald.
https://www.streetinsider.com/New+Coverage/Cantor+Fitzgerald+Starts+Immatics+%28IMTX%29+at+Overweight/22349384.html?classic=1
Articles on Eric Schmidt:
https://endpts.com/former-allogene-cfo-eric-schmidt-talks-about-his-new-role-at-cantor-and-the-future-of-cell-therapies/
https://biotuesdays.com/2023/09/06/cantor-boosts-biotech-research-with-josh-schimmer-eric-schmidt/
( all are subscription articles)
I agree. Within the next days/weeks we should hear something.
That would be great. In that case we would quickly climb above 50 and more...
I concur, sentiment reversal with buying pressure now.
According to the latest presentation, should be a clinical update in Q4/23 in IMA203 - ref. page 27
https://investors.immatics.com/static-files/0df36fcf-308b-4e29-afe7-c83c562abab6
Also, if you put the latest press release regarding RMAT designation for IMA203 into the context of the above presentation, FDA approval of IMA203 is a possibility in 2024, imo.
( that could be taken as a bold statement, however, imo IMTX is doing an awesome job in all departments.)
RMAT Press Release:
https://investors.immatics.com/news-releases/news-release-details/immatics-receives-fda-regenerative-medicine-advanced-therapy-0
Nice to see.Selling pressure seems to bei over....
IMTX Nov.3/23: Closed at $9.61 + $1.43 on 1,179,110 shares traded
Gett'in some luv here the past few days - but especially today!
Last at $9.27 + $1.09
Volume 711,357
That possibility crossed my mind as well.
However, looking at the trend in institutional selling, ie WELLINGTON/SOFINNOVA /NANTAHALA at June 30, and if that trend continued past June 30/23 ( as it appears that it has, and judging by the selling pressure sine June 30/23), this has me concerned that it is more then one seller unloading.
https://www.nasdaq.com/market-activity/stocks/imtx/institutional-holdings
One POSITIVE, from that list though, is that Baker added to their position, that instills some confidence in IMTX, imo.
Of course Nasdaq is only updated to June 30/23, so it could be considered old news.
Looking for more current institutional holdings.
This prospectus relates to the offer and sale from time to time by Bristol-Myers Squibb Company (the “selling securityholder”) of up to 2,419,818 of our ordinary shares, €0.01 nominal value per share. This prospectus also covers any additional securities that may become issuable by reason of share splits, share dividends or other similar transactions...
I think this is the reason....I believe they don't like the deal with Moderna and sell shares...
I agree, patience is key here.
All the news of collaborations/RMAT/limited data have been positive. Not understanding the stock price moves.
I've been watching for institutional share disclosures to see if an institution has been unloading, but haven't seen anything thus far.
Will post if i find anything.
I can't understand the PPS. The news was huge, I agree.
I think we have to be patient. If they go their way we'll see totally different courses here. In a view years I would not bet against a range of 50 to 100 dollars here....
IMA203 = Immatics proprietary
https://immatics.com/our-pipeline/
More data on IMA203 should be disclosed, imo.
IMTX: RMAT advantages - a few (albeit older) articles of interest:
https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/308/Breakthrough-Therapy-Designation-Regenerative-Medicine-Advanced-Therapy-Designation-Programs-in-Cellular-Gene-Therapies
https://www.raps.org/News-and-Articles/News-Articles/2018/2/RMAT-vs-Breakthrough-vs-Fast-Track-Companies-Se
https://www.pharmacytimes.com/view/regenerative-medicine-advanced-therapy-the-latest-special-fda-designation
IMTX: Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
https://www.sec.gov/Archives/edgar/data/1809196/000095010323015263/dp201755_6k.htm
HUGE news , imo
IMTX: Immatics presenting at AACR-NCI-EORTC international conference
https://investors.immatics.com/events/event-details/immatics-presenting-aacr-nci-eortc-international-conference
https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/program/#Con1
IMTX: Moderna Collaboration
https://fintel.io/doc/sec-immatics-nv-1809196-6k-2023-september-11-19611-8721?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On September 7, 2023, Immatics Biotechnologies GmbH, a subsidiary of Immatics N.V. (the “Company” or “Immatics”), entered into a Master Collaboration and License Agreement (the “Master Collaboration and License Agreement”) with ModernaTX, Inc., a subsidiary of Moderna, Inc. (“Moderna”), relating to three research programs for the development and commercialization of products employing Immatics’ and Moderna’s technologies: (i) a collaboration to discover and develop mRNA-based TCER therapeutics against targets of interest to Moderna (the “TCER Program”); (ii) the validation, generation and application of data useful for the research and development of cancer vaccines (the “Database/Vaccine Program”); and (iii) a combination therapy clinical trial with respect to IMA203 and a Moderna mRNA-based cancer vaccine (the “Clinical Combo Program”). Each research program will be governed by the Master Collaboration and License Agreement and a project agreement as described below.
Pursuant to the Master Collaboration and License Agreement, following Hart-Scott-Rodino Antitrust Improvements Act clearance, Moderna will pay to Immatics a $120 million upfront payment. In addition, as described below, Immatics may be eligible to receive development, regulatory and commercial milestone payments that could exceed $1.7 billion.
With respect to the TCER Program, pursuant to the Master Collaboration and License Agreement and the TCER Collaboration Project Agreement between the parties (the “TCER Project Agreement”), the parties will conduct the TCER Program for the research and development of TCERs with respect to HLA-presented peptide targets derived from an agreed upon number of proteins selected by Moderna. Immatics will be responsible for, and be reimbursed the cost of, TCER identification, validation and engineering to generate the applicable TCER sequence and preclinical studies in accordance with the applicable mutually agreed research plan, while Moderna will be responsible for, and bear the cost of, developing, manufacturing and commercializing the applicable products containing or comprising such TCERs; provided that Immatics has a right to co-fund the development and commercialization of certain products by making an opt-in payment in exchange for profit and loss sharing on such products. Immatics will grant to Moderna an exclusive, worldwide sublicensable license to develop, manufacture and commercialize any product (or that contain any product) developed under the TCER Project Agreement. For each target, depending on certain product characteristics, Immatics may be eligible to receive milestone payments of up to a mid-eight-digit amount upon the achievement of certain development milestones and up to a mid-nine-digit amount upon the achievement of certain regulatory and commercial milestones. In addition, during the royalty term (as described below) and depending on certain product characteristics, Immatics will be eligible to receive tiered, mid-single-digit to low-double-digit percentage royalties on worldwide net sales of the applicable product, which royalty percentages are subject to reduction in a given country under certain circumstances. A royalty term with respect to a product under the TCER Program in a given country begins upon the first commercial sale of such product in such country and terminates on the latest of the expiration of regulatory exclusivity, the expiration of valid patent claims covering such product, and 10 years after first commercial sale of the product in a given country. The TCER Project Agreement will expire upon expiration of the last royalty term contemplated by the TCER Project Agreement. During the term of the TCER Program, Immatics has certain exclusivity and notification obligations to Moderna, and its ability to develop, manufacture and commercialize certain cell therapy products that bind to the targets subject to the TCER Project Agreement is limited by the TCER Project Agreement.
With respect to the Database/Vaccine Program, pursuant to the Master Collaboration and License Agreement and the Database/Vaccine Collaboration Project Agreement between the parties (the “Database/Vaccine Project Agreement”), the parties will use Immatics’ XPRESIDENT platform to (i) generate reports for proteins or cancer vaccine candidates and validate cancer vaccine candidates (the “Database Query Program”), (ii) select peptides for respect to specific tumor types selected by Moderna for the development of cancer vaccines (the “Shared Vaccine Program”), and (iii) provide certain epitope prediction data for potential development and validation of cancer vaccines (the “Optimized Vaccine Program”). The term of these programs can be up to approximately five years. Immatics will grant to Moderna an exclusive, worldwide sublicensable license to develop, manufacture and commercialize any Shared Vaccine product or Optimized Vaccine product developed under the Database/Vaccine Project Agreement. Immatics may be eligible to receive (i) depending on the characteristics of the cancer vaccine, certain milestone payments under the Database Query Program, (ii) for each resulting cancer vaccine in the Shared Vaccine Program and the Optimized Vaccine Program, depending on certain product characteristics, up to a low-eight-digit amount upon the achievement of certain development milestones and up to a low-nine-digit amount upon the achievement of certain regulatory and commercial milestones, and (iii) for each resulting cancer vaccine in the Shared Vaccine Program, during the royalty term (as described below) and depending on certain product characteristics, tiered, low- to mid-single-digit percentage royalties on worldwide net sales of such product. A royalty term with respect to a cancer vaccine in the Shared Vaccine Program and the Optimized Vaccine Program in a given country begins upon the first commercial sale of such product in such country and
terminates on the latest of the expiration of regulatory exclusivity, the expiration of valid patent claims covering such product, and 10 years after first commercial sale of the product in a given country. During the term of the Database/Vaccine Program, Immatics has certain exclusivity obligations to Moderna, and its ability to develop certain cancer vaccines is limited by the Database/Vaccine Project Agreement.
With respect to the Clinical Combo Program, pursuant to the Master Collaboration and License Agreement and the Combination Collaboration Project Agreement between the parties (the “Clinical Combo Project Agreement”), the parties will collaborate to develop a combination therapy of IMA203 (or IMA203CD8) and a Moderna mRNA-based cancer vaccine. Immatics will be responsible for, and the parties will share the cost of, development activities in accordance with the applicable mutually agreed research plan. For so long as the parties are conducting the combination therapy clinical trial, Immatics has certain exclusivity obligations to Moderna, and its ability to develop, manufacture and commercialize combination products that involve a cancer vaccine and a cell therapy product that binds to the target of IMA203 is limited by the Clinical Combo Project Agreement.
The foregoing descriptions of the Master Collaboration and License Agreement and the project agreements thereunder do not purport to be complete and are qualified in their entirety by reference to the full text of the applicable agreements, which will be filed as an exhibit to the Company’s Annual Report on Form 20-F for the year ended December 31, 2023 or a Report on Form 6-K.
In connection with the foregoing, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1, and made available an updated investor presentation on its website, a copy of which is attached hereto as Exhibit 99.2.
INCORPORATION BY REFERENCE
This Report on Form 6-K (other than Exhibit 99.1 and 99.2 hereto) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-258351, 333-240260 and 333-274218) of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
14,46 a share! Very good sign in my opinion!
Looks like for most of June, it's been hugging the upper Bollinger/Keltner Channel ( both are similar)
The trend is looking positive ( however we know that can change at anytime), presentations and AGM are June 20/23 - few days from now.
Chart looking very promising now...hope we'll see new alltimehigh soon! But I believe...Biotech is getting popular at the moment - could give us some support too...
Looks interesting...Something coming up!
IMTX: Volume spike Friday June 16/23
Just over 2 million changed hands around $12.40 in the snap of a finger.
Looks like June is a heavy presentation month as well as the Annual General Meeting in Amsterdam, Netherlands on June 20/23.
(Are you going to that?)
https://investors.immatics.com/events-presentations
Yes, i noticed the volume as well and nice to see double digits/volume.
Nice volume today... something coming up?....
Did you notice this?
https://flashalert.me/?symbol=IMTX&source=SEC&referer=https://twitter.com/&url=https://www.sec.gov/Archives/edgar/data/1696029/000121390023010278/ea173206-13ga2dievini_immat.htm&s3=IMTX/2023-02-10/16-53-17_000000/SC%2013G/A/a7fde3b93846d15ce2863fe53eb01575/0001213900-23-010278-index.htm
Do you know anything about this organization?
https://www.dievini.de/
They are the ones reporting in the above sec filing to owning 17+ million shares of IMTX!
Good sign! Only question of time this will run...
https://markets.businessinsider.com/news/stocks/analysts-offer-insights-on-healthcare-companies-neurocrine-nbix-and-immatics-imtx-1032070272
Immatics (IMTX)
Chardan Capital analyst Keay Nakae reiterated a Buy rating on Immatics today. The company’s shares closed last Friday at $8.34.
According to TipRanks.com, Nakae is a 3-star analyst with an average return of 3.0% and a 40.3% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Better Therapeutics, Inc., and Emergent Biosolutions.
Currently, the analyst consensus on Immatics is a Moderate Buy with an average price target of $22.50.
HUGE INCREASE in institutional holdings
Check these links out:
Today's 13G filing:
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/90162993/schedule-13g-br-sc-13g
" AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,957,794" ( an increase of 4,079,134)
As of 09/30/22 re: courtesy of nasdaq
Wellington MGMT. ( 5th on the list)
1,878,660
https://www.nasdaq.com/market-activity/stocks/imtx/institutional-holdings
This puts Wellington MGMT as the largest known shareholder, at the moment.
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
162
|
Created
|
07/06/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |